| CPC B01D 9/0059 (2013.01) [B01D 9/02 (2013.01); B01D 11/0492 (2013.01); B01D 61/28 (2013.01); B01D 61/362 (2013.01); B01D 63/02 (2013.01); C07C 213/06 (2013.01); C07C 213/10 (2013.01); C07D 403/06 (2013.01); B01D 2009/0086 (2013.01)] | 15 Claims |

|
1. A method for continuous manufacturing of prexasertib monolactate monohydrate, said method comprising the steps of:
(a) combining compound 7 with hydrazine in the presence of acetic acid in methanol and THF at the temperature of about 130° C. to produce compound 8:
![]() (b) combining compound 8 with compound 9 in the presence of N-ethylmorpholine in DMSO at the temperature of about 85° C. to produce compound 10:
![]() (c) deprotecting compound 10 by combining it with formic acid at the temperature of about 25° to produce compound 1:
![]() and
(d) subjecting compound 1 to lactic acid distillation in THF/water to produce compound 12:
![]() wherein each of steps (a)-(d) is carried out in a series of units connected to each other to support continuous flow; and
wherein said series of units comprises at least one membrane-based unit, wherein after step (a), combining compound 8 with toluene and carrying out countercurrent solvent extraction using the membrane-based unit to yield compound 8 in a mixture of toluene, methanol, water and THF, wherein the membrane-based unit is a pervaporation membrane device.
|